Translate Bio Stock Forecast, Price & News

-0.06 (-0.32 %)
(As of 06/22/2021 12:08 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume14,245 shs
Average Volume1.06 million shs
Market Capitalization$1.41 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Translate Bio and its competitors with MarketBeat's FREE daily newsletter.

Translate Bio logo

About Translate Bio

Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis. It is also developing MRT5500 for the treatment of SARS-CoV-2. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. has a collaboration and license agreement with Sanofi Pasteur Inc. The company was founded in 2011 and is headquartered in Lexington, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.36 out of 5 stars

Medical Sector

798th out of 2,105 stocks

Biological Products, Except Diagnostic Industry

116th out of 198 stocks

Analyst Opinion: 3.3Community Rank: 1.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Translate Bio (NASDAQ:TBIO) Frequently Asked Questions

Is Translate Bio a buy right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Translate Bio stock.
View analyst ratings for Translate Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Translate Bio?

Wall Street analysts have given Translate Bio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Translate Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Translate Bio's next earnings date?

Translate Bio is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Translate Bio

How were Translate Bio's earnings last quarter?

Translate Bio, Inc. (NASDAQ:TBIO) issued its quarterly earnings results on Thursday, November, 5th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.20 by $0.03. The company had revenue of $66.45 million for the quarter, compared to the consensus estimate of $58.97 million. Translate Bio had a negative trailing twelve-month return on equity of 13.81% and a negative net margin of 7.69%.
View Translate Bio's earnings history

How has Translate Bio's stock been impacted by COVID-19?

Translate Bio's stock was trading at $7.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TBIO stock has increased by 150.3% and is now trading at $18.60.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TBIO?

11 analysts have issued 12 month price targets for Translate Bio's stock. Their forecasts range from $19.00 to $40.00. On average, they anticipate Translate Bio's stock price to reach $25.80 in the next twelve months. This suggests a possible upside of 38.7% from the stock's current price.
View analysts' price targets for Translate Bio
or view top-rated stocks among Wall Street analysts.

Who are Translate Bio's key executives?

Translate Bio's management team includes the following people:
  • Mr. Ronald C. Renaud Jr., CEO & Director (Age 52, Pay $885.47k)
  • Mr. Paul D. Burgess J.D., Chief Legal Officer, COO & Sec. (Age 47, Pay $596.55k)
  • Dr. Richard Wooster, Chief Scientific Officer (Age 56, Pay $596.55k)
  • Dr. Ann Barbier M.D., Ph.D., Chief Medical Officer (Age 57, Pay $610.55k)
  • Dr. E. Rand Sutherland, Pres
  • Mr. Brendan Smith M.B.A., CFO, Corp. Strategy & Principal Financial Officer (Age 45)
  • Mr. Robert D. Prentiss, VP, Corp. Controller, Treasurer & Interim Principal Accounting Officer (Age 49)
  • Mr. Frank DeRosa, Chief Technology Officer
  • Ms. Teri Babine Dahlman, VP of Corp. Communications & Investor Relations
  • Ms. Paula A. Cloghessy, Chief People Officer (Age 50)

What is Craig J. Tuttle's approval rating as Translate Bio's CEO?

13 employees have rated Translate Bio CEO Craig J. Tuttle on Craig J. Tuttle has an approval rating of 5% among Translate Bio's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Translate Bio's key competitors?

What other stocks do shareholders of Translate Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA), Johnson & Johnson (JNJ), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and VBI Vaccines (vbiv).

When did Translate Bio IPO?

(TBIO) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.

What is Translate Bio's stock symbol?

Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."

Who are Translate Bio's major shareholders?

Translate Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.59%), RTW Investments LP (5.82%), Federated Hermes Inc. (4.92%), Price T Rowe Associates Inc. MD (2.40%), Goldman Sachs Group Inc. (2.12%) and Geode Capital Management LLC (1.54%). Company insiders that own Translate Bio stock include Baupost Group Llc/Ma, Human Genetic Therapies Shire and Jean Francois Formela.
View institutional ownership trends for Translate Bio

Which institutional investors are selling Translate Bio stock?

TBIO stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Barclays PLC, Acadian Asset Management LLC, Millennium Management LLC, Credit Suisse AG, Cubist Systematic Strategies LLC, Northern Trust Corp, and Allianz Asset Management GmbH. Company insiders that have sold Translate Bio company stock in the last year include Human Genetic Therapies Shire, and Jean Francois Formela.
View insider buying and selling activity for Translate Bio
or view top insider-selling stocks.

Which institutional investors are buying Translate Bio stock?

TBIO stock was acquired by a variety of institutional investors in the last quarter, including RTW Investments LP, Camber Capital Management LP, Federated Hermes Inc., Goldman Sachs Group Inc., EcoR1 Capital LLC, JPMorgan Chase & Co., BlackRock Inc., and Morgan Stanley.
View insider buying and selling activity for Translate Bio
or or view top insider-buying stocks.

How do I buy shares of Translate Bio?

Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Translate Bio's stock price today?

One share of TBIO stock can currently be purchased for approximately $18.60.

How much money does Translate Bio make?

Translate Bio has a market capitalization of $1.40 billion and generates $138.81 million in revenue each year. The company earns $-53,790,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

How many employees does Translate Bio have?

Translate Bio employs 122 workers across the globe.

What is Translate Bio's official website?

The official website for Translate Bio is

Where are Translate Bio's headquarters?

Translate Bio is headquartered at 29 HARTWELL AVENUE, LEXINGTON MA, 02421.

How can I contact Translate Bio?

Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361.

This page was last updated on 6/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.